Tag: Hiv lipodystrophy

Tesamorelin, an FDA-approved growth hormone-releasing factor analog, has been clinically shown to significantly reduce visceral adipose tissue (VAT) by an average of 15–20% over 26 weeks in patients with HIV-associated lipodystrophy. This peptide's effectiveness lies in its targeted action on deep abdominal fat and its subsequent metabolic improvements.

According to manufacturer guidelines, the specific amount of water for tesamorelin reconstitution depends entirely on the formulation being used. This crucial detail is often overlooked and can lead to incorrect preparation, so understanding the product-specific instructions is essential for patient safety.

While both AOD-9604 and Tesamorelin are peptides explored for metabolic effects, a key fact is that Tesamorelin is an FDA-approved medication, while AOD-9604 remains an unapproved research compound. This fundamental distinction dictates their mechanisms, clinical applications, and safety profiles, highlighting the core difference between AOD-9604 and Tesamorelin.

Clinical trials show that discontinuing tesamorelin, a treatment for HIV-associated lipodystrophy, leads to a reaccumulation of visceral fat, highlighting the need for ongoing therapy to sustain benefits. This makes the question of "how long can I stay on tesamorelin?" crucial for patients considering this medication.

While both Tesamorelin and Ozempic are injectable medications, a 2025 review found they are fundamentally different drugs used to treat different conditions. Is Tesamorelin like Ozempic? In short, no, and understanding their distinctions is crucial for patients and healthcare providers.